Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Given Consensus Recommendation of “Buy” by Analysts

Shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) have been given a consensus recommendation of “Buy” by the nine research firms that are currently covering the firm, MarketBeat Ratings reports. Eight research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $12.6250.

Several research analysts have weighed in on CATX shares. B. Riley Financial upped their price objective on shares of Perspective Therapeutics from $11.00 to $13.00 and gave the stock a “buy” rating in a report on Wednesday, March 18th. BTIG Research reiterated a “buy” rating and issued a $14.00 target price on shares of Perspective Therapeutics in a research note on Tuesday, March 17th. HC Wainwright upped their target price on shares of Perspective Therapeutics from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Monday, March 23rd. Wedbush reiterated an “outperform” rating and issued a $11.00 target price on shares of Perspective Therapeutics in a research note on Monday. Finally, Piper Sandler assumed coverage on shares of Perspective Therapeutics in a research note on Thursday, February 19th. They issued an “overweight” rating and a $16.00 target price for the company.

Institutional Trading of Perspective Therapeutics

Several institutional investors have recently made changes to their positions in CATX. Geode Capital Management LLC grew its stake in shares of Perspective Therapeutics by 15.8% in the 2nd quarter. Geode Capital Management LLC now owns 1,382,814 shares of the company’s stock worth $4,758,000 after acquiring an additional 188,887 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of Perspective Therapeutics by 118.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 748,067 shares of the company’s stock worth $2,573,000 after acquiring an additional 405,612 shares in the last quarter. Walleye Capital LLC grew its stake in shares of Perspective Therapeutics by 375.8% in the 2nd quarter. Walleye Capital LLC now owns 187,403 shares of the company’s stock worth $645,000 after acquiring an additional 148,013 shares in the last quarter. Federated Hermes Inc. grew its stake in shares of Perspective Therapeutics by 44.4% in the 2nd quarter. Federated Hermes Inc. now owns 195,080 shares of the company’s stock worth $671,000 after acquiring an additional 60,019 shares in the last quarter. Finally, Bank of America Corp DE grew its stake in shares of Perspective Therapeutics by 8.5% in the 2nd quarter. Bank of America Corp DE now owns 327,500 shares of the company’s stock worth $1,127,000 after acquiring an additional 25,697 shares in the last quarter. Institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Stock Performance

CATX opened at $4.64 on Wednesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.17 and a current ratio of 5.17. The company’s fifty day moving average price is $4.77 and its two-hundred day moving average price is $3.60. Perspective Therapeutics has a 1-year low of $1.93 and a 1-year high of $6.16.

Perspective Therapeutics (NYSEAMERICAN:CATX) last released its quarterly earnings data on Monday, March 16th. The company reported ($0.51) earnings per share for the quarter. Perspective Therapeutics had a negative return on equity of 41.79% and a negative net margin of 11,665.27%.The business had revenue of $0.04 million for the quarter. As a group, equities research analysts expect that Perspective Therapeutics will post -1.17 earnings per share for the current year.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.